

PTO/SBDBb (08-03)

Approved for use through 06/30/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/632,998
		Filing Date	August 1, 2003
		First Named Inventor	Cirillo, P. et al
		Art Unit	To be assigned 1626
		Examiner Name	To be assigned G. Shameem
Sheet	1	of	1
		Attorney Docket Number	9/255

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CS		CHODOROWSKA, Grazyna; Plasma concentrations of IFN- $\gamma$ and TNF- $\alpha$ in psoriatic patients before and after local treatment with dithranol ointment. Journal of European Academy of Dermatology and Venerology; 10 (1998) 147-151	
		HIGHAM, M.A., et al; Tumour necrosis factor- $\alpha$ gene promoter polymorphism in chronic obstructive pulmonary disease. Euro Respir. J 2000; 15: 281-284	
		TAKABATAKE, N., et al; The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor- $\alpha$ System in Patients with Chronic Obstructive Pulmonary Disease; American Journal of Respiratory and Critical Care Medicine; Vol. 161, 1179-1184	
CS		Tumor Necrosis Factor Inhibitors - Rx Intelligence - Early Alert Report - Executive Summary	

Examiner Signature	<i>G. Shameem</i>	Date Considered	11/22/04
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.